Real-World Single-Center Clinical Data on Sorafenib in Patients with Unresectable Hepatocellular Carcinoma

Author(s) :

Catalin Stefan Ghenea1, Stefania Dumitrescu2, Livia Marieta Negoita1, Mariana Mihaila3, Livia Carmen Albu3, Gabriel Constantinescu1,4

1Clinical Department of Gastroenterology, Bucharest Emergency Clinical Hospital, Romania

2Department of Oncology, Fundeni Clinical Institute, Bucharest, Romania

3Center of Internal Medicine, Fundeni Clinical Institute, Bucharest, Romania

4University of Medicine and Pharmacy Carol Davila Bucharest, Romania

Corresponding author: Ștefania Dumitrescu, Email:

Published: Volume II, Issue 1, July 2022, 18-26 , , , - DOI:

Open Access

Full text


July 1, 2022 0 Comments


Introduction. Hepatocellular carcinoma (HCC) is a malignant tumor that frequently develops in conjunction with chronic liver disease and cirrhosis, and is often identified late in its course, with a median survival of around 6 to 20 months following diagnosis. Although surgical excision is the gold standard of treatment, most patients are ineligible due to tumor size or underlying liver dis-ease. The hepatic reserve of the patient, as determined by the Child-Turcotte-Pugh classification, frequently influences treatment options.
Method. Between January 2016 and June 2018, 42 patients admitted to Fundeni Clinical Institute’s Department of Medical Oncology who had previously been treated with Sorafenib for more than two months were recruited in this retrospective analysis. We evaluated the etiology and stage of illness (BCLC), residual liver function (CHILD), performance status (ECOG), treatment response and side effects, progression-free survival, and overall survival.
Results. The study group had good short and long-term outcomes: median progression-free survival was 7.7 months and median overall survival was 11.6 months. The most frequently reported adverse effects were skin rashes, diarrhea, hypertension, and hand-foot skin reaction.
Conclusion. This retrospective, single-center study confirmed the benefit of sorafenib in the treatment of advanced HCC, particularly in patients with good liver function and performance status.

Notify of
Inline Feedbacks
View all comments